Atherosclerosis: perspectives of anti-inflammatory therapy


Cite item

Full Text

Abstract

According to modern ideas, chronic low-grade inflammation, which development is associated with uncontrolled activation of both innate and adaptive immunity, plays a fundamental role in all stages of the atherosclerotic process. The contribution of inflammation to the development of atherosclerotic vascular lesions attracts attention to the similarity of the mechanisms of immunopathogenesis of atherosclerosis and classic inflammatory rheumatic disease - rheumatoid arthritis. In the aspect of participation in the pathogenesis of atherosclerotic vascular lesions and as a promising therapeutic "target" of particular interest is interleukin-1β (IL-1β), which plays an important role in the development of many acute and chronic immunosuppressive diseases. The mechanisms of atherosclerosis associated with IL-1β determine the ability of cholesterol crystals and other "Pro-atherogenic" factors to induce the synthesis of IL-1β by activating NLRP3 inflammasome. The mechanisms of atherosclerosis associated with IL-1β determine the ability of cholesterol crystals and other "proatherogenic" factors to induce the synthesis of IL-1β by activating NLRP3 inflammasome. Convincing evidence for the role of inflammation in development of atherosclerosis in General and good prospects of anti-inflammatory therapy in particular obtained in a randomized placebo-controlled study called CANTOS (Canakinumab Anti-inflammatory Thrombosis Otcomes Study), which studied the effectiveness of treatment with monoclonal antibodies to IL-1β canakinumab (Novartis International AG) in patients with severe atherosclerotic vascular lesions as a new approach to secondary prevention of cardiovascular complications. The results of CАNTOS research, as well as the experience gained in rheumatology in regard to cardiovascular effects of innovative anti-inflammatory drugs, have great importance for the improvement of secondary prevention of atherosclerosis-related cardiovascular complications.

About the authors

E L Nasonov

V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University

Email: nasonov@irramn.ru
научный руководитель ФГБНУ «Научно-исследовательский институт им. В.А. Насоновой» Moscow, Russia

T V Popkova

V.A. Nasonova Research Institute of Rheumatology

д.м.н., руководитель лаб. системных ревматических заболеваний с группой гемореологических нарушений, ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» Moscow, Russia

References

  1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999; 340: 419-20. doi: 10.1016/S0002-8703(99)70266-8
  2. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352: 1685-1695.
  3. Libby P, Ridker P.M, Hansson G.K. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009; 54: 2129-2138.
  4. Pasceri V, Yeh E.T. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation. 1999; 100:2124-6. doi: 10.1161/01.CIR. 100.21.2124
  5. Sattar N, Mc Carey D.W, Capell H, McInnes I.B. Explaining how “high - grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003; 108:2957-2963.
  6. Насонов Е.Л. Проблема атеротромбоза в ревматологии. Вестник РАМН. 2003; (7):6-10.
  7. Насонов Е.Л., Попкова Т.В., Новикова Д.С. Сердечно - сосудистая патология при ревматических заболеваниях. Терапевтический архив. 2016; (5):3-10.
  8. Nurmohamed M.T, Heslinga M, Kitas G.D. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol. 2015; 11: 693-704.
  9. Lindhardsen J, Ahlehoff O, Gislason G.H et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis. 2011; 70:929-34. doi:10.1136/ ard.2010.143396
  10. Arts E.E, Fransen J, Den Broeder A.A, van Riel P.L.C.M, Popa C.D. Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time - dependent Cox regression analysis in a large cohort study. Ann Rheum Dis. 2017; 76(10):1693-1699. doi: 10.1136/annrheumdis-2016-210997
  11. Arida A, Protogerou A.D, Konstantonis G, Fragiadaki K, Kitas G.D, Sfikakis P.P. Atherosclerosis is not accelerated in rheumatoid arthritis of low activity or remission, regardless of antirheumatic treatment modalities. Rheumatology (Oxford). 2017; 56(6):934-939. doi: 10.1093/rheumatology/kew506.
  12. Solomon D.H, Reed G.W, Kremer J.M et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheum. 2015; 67(6):1449-55. doi: 10.1002/art.39098
  13. Kokkonen H, Stenlund H, Rantapää-Dahlqvist S. Cardiovascular risk factors predate the onset of symptoms of rheumatoid arthritis: a nested case - control study. Arthritis Res Ther. 2017; 19(1):148. doi: 10.1186/s 13075-017-1351-8.
  14. Myasoedova E. Lipids and lipid changes with synthetic and biologic disease - modifying antirheumatic drug therapy in rheumatoid arthritis: implications for cardiovascular risk. Curr Opin Rheumatol. 2017; 29(3):277-84. doi: 10.1097/BOR.0000000000000378
  15. Mason J.C, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J. 2015; 36(8):482-9c. doi: 10.1093/eurheartj/ehu403
  16. Vázquez-Del Mercado M, Nuñez-Atahualpa L, Figueroa-Sánchez M et al. Serum levels of anticyclic citrullinated peptide antibodies, interleukin-6, tumor necrosis factor - α, and C-reactive protein are associated with increased carotid intima - media thickness: a cross - sectional analysis of a cohort of rheumatoid arthritis patients without cardiovascular risk factors. Biomed Res Int. 2015;2015:342649.
  17. Spinelli F.R, Pecani A, Ciciarello F et al. Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patients. BMS Musculoskeletal disorders. 2017; 18: 214. 2017 May 25. doi: 10.1186/s12891-017-1563-8
  18. Geraldino-Pardilla L, Giles J.T, Sokolove J, Zartoshti A, Robinson W.H, Budoff M, Detrano R, Bokhari S, Bathon J.M. Association of Anti-Citrullinated Peptide Antibodies With Coronary Artery Calcification in Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2017; 69(8):1276-1281. doi: 10.1002/acr.23
  19. Okano T, Inui K, Sugioka Y, Sugioka K, Matsumura Y, Takahashi S, Tada M, Mamoto K, Wakitani S, Koike T, Nakamura H. High titer of anti - citrullinated peptide antibody is a risk factor for severe carotid atherosclerotic plaque in patients with rheumatoid arthritis: the TOMORROW study. Int J Rheum Dis. 2017; 20(8):949-959. doi: 10.1111/1756-185X.13106.
  20. Hermans M.P.J, van der Velden D, Montero Cabezas J.M.M., Putter H et al. Long - term mortality in patients with ST-segment elevatiob myocardial infarction is associated with anti - citrullinated protein antibodies. Int J Cardiol. 2017; 240: 20-24.
  21. Ridker P.M. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J. 2016;37:1720-2. doi: 10.1093/eurheartj/ehw024
  22. Fatkhullina A.R, Peshkova I.O, Koltsova E.K. The Role of Cytokines in the Development of Atherosclerosis. Biochemistry (Mosc). 2016; 81(11):1358-1370.
  23. Van Tassel B.W, Toldo S, Mezzaroma E, Abbate A. Targeting interleukin-1 in heart disease. Circulation. 2013; 128:1910-23. doi: 10.1161/CIRCULATION.113.003199
  24. Libby P.J. A Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond. J Amer Coll Cardiol. 2017; 31;70(18):2278-2289. doi: 0.1016/j.jacc.2017.09.028
  25. Ridker P.M. From C-reactive protein to interleukin-6 to interleukin-1: Moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145-56. doi: 10.1161/CIRCRESAHA.115. 306656
  26. Ray M, Autieri M.V. Regulation of pro - and anti - atherogenic cytokines. Cytokines. 2017 Dec 6. pii: S1043-4666(17)30289-2. doi: 10.1016/j. cyto. 2017.09.031
  27. Reis A, Siegat N.M, de Leon J. Interkeukin-6 in atherosclerosis: atherogenic or atheroprotective. Clin Lipidol. 2017; 12:14023.
  28. van der Heijden T, Bot I, Kuiper J. The IL-12 cytokine family in cardiovascular diseases. Cytokine. 2017 pii: S1043-4666(17)30315-0. doi: 10.1016/j.cyto.2017.10.010.
  29. Damen M.S.M.A, Popa C.D, Netea M.G, Dinarello C.A, Joosten L.A.B. Interleukin-32 in chronic inflammatory conditions is associated with a higher risk of cardiovascular diseases. Atherosclerosis. 2017;264:83-91. doi: 10.1016/j.atherosclerosis.2017.07.005
  30. Robert M, Miossec P. Effects of interleukin 17 on the cardiovascular system. Autoimmun Rev. 2017; 16:984-91. doi: 10.1016/j. autrev.2017.07.009
  31. Zhuang X, Wu B, Li J, Shi H, Jin B, Luo X. The emerging role of interleukin-37 in cardiovascular diseases. Immun Inflamm Dis. 2017; 5(3):373-379. doi: 10.1002/iid3.159
  32. Dinarello C.A. An expanding role for interleukin-1 blockade from gout to cancer. Molecular Med. 2014; 20 (Suppl 1):S43-S58. doi: 10.2119/molmed.2014.00232
  33. Насонов Е.Л., Елисеев М.С. Роль интерлейкина 1 в развитии заболеваний человека. Научно - практическая ревматология. 2016;54(1):60-77. doi:10.14412/ 1995-4484-2016-60-77
  34. Karasawa T, Takahashi M. Role of NLRP3 inflammasomes in atherosclerosis. J Atheroscler Thromb. 2017; 24(5):443-51. doi: 10.5551/jat.RV17001
  35. Hunter C.A, Jones S.A. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015; 15: 448-457. doi: 10.1038/ni1117-1271b
  36. Попкова Т.В., Новикова Д.С., Насонов Е.Л. Интерлейкин 6 и сердечно - сосудистая патология при ревматоидном артрите. Научно - практическая ревматология. 2011; 4: 64-72.
  37. Pokharel Y, Sharma P.P, Qintar M et al. High - sensitivity C-reactive protein levels and health status outcomes after myocardial infarction. Atherosclerosis. 2017; 266:16-23.
  38. Wang A, Liu J, Li C et al. Cumulative exposure to high - sensitivity C-reactive protein predicts the risk of cardiovascular disease. J Am Heart Assoc. 2017; 6: e005610.
  39. Ridker P.M. A test in context. High - sensitive C-reactive protein. J Amer Coll Cardiol. 2016; 67: 712-723.
  40. Braunwald E. Creating controversy wh ere none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials. Eur Heart J. 2012; 33: 430-432.
  41. Bohula E.A, Giugliano R.P, Cannon C.P et al. Achievement of dual low - density lipoprotein cholesterol and high - sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015; 132: 1224-1233.
  42. Navarro-Millan I, Yang S, Du Vall S.L, Chen L, Baddley J, Cannon G.W, Delzell E.S, Zhang J, Safford M.M, Patkar N.M, Mikuls T.R, Singh J.A, Curtis J.R. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. Ann Rheum Dis. 2016;75:341-7.
  43. Meissner Y, Angela Zink A, Kekow J, Rockwitz K, Liebhabe A et al. Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis. Arthritis Research Ther. 2016; 18:183. https://doi.org/10.1186/s13075-016-1077-z
  44. Sarwar N, Butterworth A.S, Freitag D.F, Gregson J, Willeit P et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta - analysis of 82 studies. Lancet. 2012; 379:1205-13.
  45. Held C, White H.D, Stewart R.A.H, Budaj A, Cannon C.P et al. STABILITY Investigators. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017; 6(10). pii: e005077. doi: 10.1161/JAHA.116.005077
  46. Curtis J.R, Xie F Chen L, Saag K.G, Yun H, Muntner P. Biomarker - related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population - based study. 2017 Dec 21. pii: annrheumdis-2017-211727. doi: 10.1136/annrheumdis-2017-211727
  47. Gram H. Preclinical characterization and clinical development of ILARIS® (canakinumab) for the treatment of autoinflammatory diseases. Curr Opin Chem Biol. 2016; 32:1-9. doi: 10.1016/j.cbpa.2015.12.003
  48. Cavalli G, Dinarello C.A. Treating rheumatological diseases and co - morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford). 2015; 54(12):2134-44. doi: 10.1093/rheumatology/kev269
  49. Alten R, Gomez-Reino J, Durez P, Beaulieu A, Sebba A, Krammer G, Preiss R, Arulmani U, Widmer A, Gitton X, Kellner Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose - finding study. BMS musculoskeletal Disord. 2011; 12:153. doi: 10.1186/1471-2474-12-153
  50. Demin I, Hamren B, Luttringer O et al. Longitudinal model - based meta - analysis in rheumatoid arthritis: an application toward model - based drug development. Clinical Pharm Ther. 2012; 92:352-9. doi: 10.1038/clpt.2012.69
  51. Ridker P.M, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti - inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011; 162:597-605. doi: 10.1016/j.ahj. 2011.06.012
  52. Ridker P.M, Howard C.P, Walter V et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo - controlled trial. Circulation. 2012; 126:2739-48. doi: 10.1161/CIRCULATIONAHA.112.122556
  53. Ridker P.M, Everett B.M, Thuren T et al. CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 Aug 27. doi: 10.1056/NEJMoa1707914
  54. Ridker P.M, Mac Fadyen J.G, Thuren T et al. CANTOS Trial Group. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double - blind, placebo - controlled trial. Lancet. 2017 Aug 25. doi: 10.1016/S0140-6736(17)32247-X
  55. Ridker P.M, Mac Fadyen J.G, Everett B.M, Libby P, Thuren T, Glynn R.J. CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2017 Nov 13. pii: S0140-6736(17)32814-3. doi: 10.1016/ S0140-6736(17)32814-3
  56. Nissen S.E, Tuzcu E.M, Schoenhagen P et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005; 352: 29-38.
  57. Grivennikov S.I, Greten F.R, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140:883-99. doi: 10.1016/j.cell.2010.01.025
  58. Herder C, Dalmas E, Boni-Schnetzler M, Donath M.Y. The IL-1 pathway in type 2 diabetes and cardiovascular complications. Trends Endocrinol Metasb. 2015; 26:551-63. doi: 0rg/10.1016/j.tem.2015.08.001
  59. Rissanen A, Howard C.P, Botha J, Thuren T. Global Investigators. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo - controlled trial. Diabetes Obes Metab. 2012; 14:1088-96. doi: 10.1111/j.1463-1326.2012.01637.x
  60. Hensen J, Howard C.P, Walter V, Thuren T. Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo - controlled trial. Diabetes Metab. 2013; 39:524-31. doi: 10.1016/j.diabet.2013.07.003
  61. Stahel M, Becker M, Graf N, Michels S. Systemic interleukin 1β inhibition in proliferative diabetic retinopathy: A Prospective Open-Label Study Using Canakinumab. Retina. 2016 Feb; 36(2):385-91. doi: 10.1097/IAE.0000000000000701.
  62. Rock K.L, Kataoka H, Lai J-J. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol. 2013; 9:13-23. doi: 10.1038/nrheum.2012/143
  63. Елисеев М.С., Желябина О.В., Маркеловa Е.И. и др. Оценка кардиоваскулярного риска при применении ингибитора интерлейкина 1 у больных тяжелой тофусной подагрой. Современная ревматология. 2016; 10(1):7-14. doi: 10.14412/1996-7012-2016-1-7-14
  64. Leung Y.Y, Hui L.L.Y, Kraus V.B. Colchicine - update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015; 45(3):341-50. doi: 10.1016/j.semarthrit.2015.06.013
  65. Crittenden D.B, Lehmann R.A, Schneck L et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012; 39:1458-64. doi: 10.3899/jrheum. 111533
  66. Solomon D.H, Liu C.C, Kuo I.H et al. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016; 75(9):1674-9. doi: 10.1136/annrheumdis-2015-207984
  67. Demidowich A.P, Davis A.I, Dedhia N, Yanovski J.A. Colchicine to decrease NLRP3-activated inflammation and improve obesity - related metabolic dysregulation. Med Hypotheses. 2016; 92:67-73. doi: 10.1016/j.mehy.2016.04.039
  68. Martinez G.J, Robertson S, Barraclough J, Xia Q, Mallat Z, Bursill C, Celermajer D.S, Patel S. Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome. J Am Heart Assoc. 2015; 4:e002128. doi:10/1161/JAHA.115.002128
  69. Robertson S, Martínez G.J, Payet C.A, Barraclough J.Y, Celermajer D.S, Bursill C, Patel S. Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation. Clin Sci (London). 2016; 130(14):1237-46. doi: 10.1042/ CS20160090
  70. Nidorf S.M, Eikelboom J.W, Budgeon C.A, Thompson P.L. Low - dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013; 61:404-10. doi: 10.1016/j.jacc.2012.10.027
  71. Vaidya K, Arnott C, Martínez G.J, Ng B, Mc Cormack S, Sullivan D.R et al. Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study. JACC Cardiovascular Imaging. 2017 Oct 14. pii: S1936-878X(17)30791-X. doi: 10.1016/j.jcmg.2017.08.013
  72. Deftereos S, Giannopoulos G, Angelidis C, Alexopoulos N, Filippatos G et al. Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study. Circulation. 2015; 132:1395-403. doi: 10.1161/CIRCULATIONAHA.115.017611
  73. Tousoulis D, Oikonomou E, Economou E.K et al. Inflammatory cytokines in atherosclerosis: current therapeutic approaches. Eur Heart J. 2016; 37:1723-32. doi: 10.1093/eurheartj/ehv759
  74. Насонов Е.Л., редактор. Генно - инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013.
  75. Charles-Schoeman C, Gonzalez-Gay M.A, Kaplan I, Boy M, Geier J, Luo Z, Zuckerman A, Riese R. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Semin Arthritis Rheum. 2016; 46(1):71-80. doi: 10.1016/j.semarthrit.2016.03.004
  76. Strang A.C, Bisoendial R.J, Kootte R.S, Schulte D.M, Dallinga-Thie G.M, Levels J.H, Kok M, Vos K, Tas S.W, Tietge U.J, Muller N, Laudes M, Gerlag D.M, Stroes E.S, Tak P.P. Pro - atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis. 2013; 229:174-81.
  77. McInnes I.B, Thompson L, Giles J.T, Bathon J.M, Salmon J.E, Beaulieu A.D, Codding C.E, Carlson T.H, Delles C, Lee J.S, Sattar N. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo - controlled study. Ann Rheum Dis. 2015; 74:694-702.
  78. Ruiz-Limón P, Ortega R, Arias de la Rosa I, Abalos-Aguilera M.D.C, Perez-Sanchez C et al. Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. Trans Resl. 2017; 183:87-103. doi: 10.1016/j.trsl.2016.12.003
  79. García-Gómez C, Martín-Martínez M.A, Castañeda S, Sanchez-Alonso F, Uriarte-Ecenarro M et al.CARMA Project Collaborative Group. Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project. J Clin Lipidol. 2017; 11(3):749-756. e3. doi: 10.1016/j.jacl.2017. 02.018
  80. Bacchiega B.C, Bacchiega A.B, Usnayo M.J, Bedirian R, Singh G, Pinheiro G.D. Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study. J Amer Heart Assoc. 2017; 6(3). pii: e005038. doi: 10.1161/JAHA.116.005038
  81. Gabay C, McInnes I.B, Kavanaugh A, Tuckwell K, Klearman M, Pulley J, Sattar N. Comparison of lipid and lipid - associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2016; 75(10):1806-12. doi: 10.1136/annrheumdis-2015-207872
  82. Kleveland O, Kunszt G, Bratlie M, Ueland T, Broch K, Holte E, Michelsen A.E, Bendz B, Amundsen B.H, Espevik T, Aakhus S, Damås J.K, Aukrust P, Wiseth R, Gullestad L. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double - blind, randomized, placebo - controlled phase 2 trial. Eur Heart J. 2016; 37(30):2406-13. doi: 10.1093/eurheartj/ehw171
  83. Robertson J, Porter D, Sattar N, Packard C.J, Caslake M, McInnes I, McCarey. Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine - specific mechanism for cholesterol changes in rheumatoid arthritis. Ann Rheum Dis. 2017; 76(11):1949-1952. doi: 10.1136/annrheumdis-2017-21170
  84. Rao V.U, Pavlov A, Klearman M, Musselman D, Giles J.T, Bathon J.M et al. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheumatol. 2015; 67:372-80.
  85. Kim S.C, Solomon D.H, Rogers J.R, Gale S, Klearman M. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. Arthritis Rheum. 2017; 69: 1154-1164. doi: 10.1002/art.40084
  86. Giles J.T, Sattar N, Gabriel S.E, Ridker P.M, Gay S, Warne C, Musselman D, Brockwell L, Shittu E, Klearman M, Fleming T. Comparative Cardiovascular Safety of Tocilizumab Vs Etanercept in Rheumatoid Arthritis: Results of a Randomized, Parallel-Group, Multicenter, Noninferiority, Phase 4 Clinical Trial [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).
  87. Kraakman M.J, Dragoljevic D, Kammoun H.L, Murphy A.J. Is the risk of cardiovascular disease altered with anti - inflammatory therapies? Insights from rheumatoid arthritis. Clin Transl Immunol. 2016; 5(5):e84. doi: 10.1038/cti.2016.31

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies